These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 23669782)

  • 1. Canaglifozin (Invokana) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1416):37-9. PubMed ID: 23669782
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel approach.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):32-4. PubMed ID: 23802291
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating type 2 diabetes with canagliflozin.
    Van Gilder D; Jungemann S
    S D Med; 2013 Jul; 66(7):280-1. PubMed ID: 23957114
    [No Abstract]   [Full Text] [Related]  

  • 4. Canagliflozin: a new drug for type 2.
    Goldman-Levine J
    Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
    [No Abstract]   [Full Text] [Related]  

  • 5. Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
    Takeuchi T; Dohi K; Omori T; Moriwaki K; Sato Y; Nakamori S; Fujimoto N; Fujii E; Yamada N; Ito M
    Int J Cardiol; 2015 Dec; 201():1-3. PubMed ID: 26278671
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
    Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
    Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
    Washburn WN
    J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
    [No Abstract]   [Full Text] [Related]  

  • 8. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin (Jardiance) for diabetes.
    Med Lett Drugs Ther; 2014 Oct; 56(1453):99-100. PubMed ID: 25296258
    [No Abstract]   [Full Text] [Related]  

  • 10. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543.
    Ikegai K; Imamura M; Suzuki T; Nakanishi K; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2013 Jul; 21(13):3934-48. PubMed ID: 23651509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
    Ohtake Y; Sato T; Kobayashi T; Nishimoto M; Taka N; Takano K; Yamamoto K; Ohmori M; Yamaguchi M; Takami K; Yeu SY; Ahn KH; Matsuoka H; Morikawa K; Suzuki M; Hagita H; Ozawa K; Yamaguchi K; Kato M; Ikeda S
    J Med Chem; 2012 Sep; 55(17):7828-40. PubMed ID: 22889351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
    Takasu T; Takakura S; Kaku S
    Nihon Yakurigaku Zasshi; 2015 Jan; 145(1):36-42. PubMed ID: 25743234
    [No Abstract]   [Full Text] [Related]  

  • 17. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
    Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
    Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glyxambi--a new combination for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):65-6. PubMed ID: 25897551
    [No Abstract]   [Full Text] [Related]  

  • 19. [Canagliflozin. For treating diabetes].
    Sabourin G
    Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.